TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10974616

Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4) injection, high doses, specific dosage not mentioned, duration not mentioned.
Number of subjects: 0
Study: 8868035

Group type: EXPERIMENTAL
Intervention: Spectrophotometric examination of tape strips
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weighing method
Number of subjects: 0
Study: 1611113

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)‐alpha 2b (50 MU dose), intravesical therapy for 10 months, starting 21 days after TUR, once a week for 8 weeks, then once every 15 days for 4 months, and finally once a month for 4 months.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Epirubicin (80 mg) intravesically 0, 24 and 48 h after TUR, followed by IFN‐alpha 2b as in Group 1.
Number of subjects: 85
Study: 31959339

Group type: EXPERIMENTAL
Intervention: Cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1-4 (CF)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1-4 plus panitumumab (P) 9 mg/kg, i.v., day 1 (CFP)
Number of subjects: 142
Study: 30967434

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 1591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 mg and 10 mg combined)
Number of subjects: 1591
Study: 28079812

Group type: EXPERIMENTAL
Intervention: Elastomeric patient-control module (PCM) connected to balloon pump
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional patient-control module (PCM) connected to balloon pump
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Elastomeric patient-control module (PCM)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional patient-control module (PCM)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both elastomeric and conventional PCM
Number of subjects: 86
Study: 25666934

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 23452148

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 21352528

Group type: EXPERIMENTAL
Intervention: Decision Support Package (DSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19884426

Group type: EXPERIMENTAL
Intervention: Periarticular injections with corticosteroid (methylprednisolone acetate)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Periarticular injections without corticosteroid (no-steroid group)
Number of subjects: 76
Study: 17537264

Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/day for 3 consecutive days)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 443
Study: 15581128

Group type: EXPERIMENTAL
Intervention: Boundary constraints applied to event dating
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Removal of guesses from the data set
Number of subjects: 200
Study: 11329985

Group type: EXPERIMENTAL
Intervention: Monthly group visits with a primary care physician, nurse, and pharmacist
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 295
Study: 9741191

Group type: EXPERIMENTAL
Intervention: Thermovision testing during rehabilitation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 71
Study: 7988347

Group type: EXPERIMENTAL
Intervention: Pancreatic elastase (10,800 U)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Dilazep dihydrochloride (300 mg)
Number of subjects: 28
Study: 3052894

Group type: EXPERIMENTAL
Intervention: Cefotetan (CTT) 2g single preoperative dose
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cefoxitin (CFX) 2g three perioperative doses plus 0.5g metronidazole
Number of subjects: 102
Study: 30870012

Group type: EXPERIMENTAL
Intervention: Integrative care intervention delivered by naturopathic doctors (NDs) in conjunction with usual care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study: 28566227

Group type: EXPERIMENTAL
Intervention: Boosted protease inhibitor plus lamivudine (once-daily lamivudine 300 mg)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Boosted protease inhibitor monotherapy (once-daily darunavir 800 mg or coformulation of lopinavir/ritonavir)
Number of subjects: 265
Study: 26359220

Group type: EXPERIMENTAL
Intervention: Self-management group (SG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 0
Study: 24364193

Group type: EXPERIMENTAL
Intervention: Complex oral splint procedure assisted by transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard oral splint
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects (baseline values)
Number of subjects: 20
Study: 20890666

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy for 12 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no PAP therapy)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy
Number of subjects: 18
Study: 19682889

Group type: EXPERIMENTAL
Intervention: 3D-CRT (70Gy, 74Gy, 78Gy)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: IMRT (74Gy, 78Gy)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: 3D-CRT
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: RT up to 78Gy
Number of subjects: 791

Group type: COMPARATOR
Intervention: Hormonal treatment
Number of subjects: 791
Study: 17090955

Group type: EXPERIMENTAL
Intervention: Levothyroxine replacement
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 90
Study: 15314303

Group type: EXPERIMENTAL
Intervention: Exchange of saline during gastrectomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: No exchange of saline during gastrectomy (Control)
Number of subjects: 34
Study: 11349245

Group type: EXPERIMENTAL
Intervention: Weekly sessions plus routine inpatient treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine inpatient treatment only
Number of subjects: 50
Study: 9152658

Group type: EXPERIMENTAL
Intervention: Intravenous procainamide (10 mg.kg‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7700072

Group type: EXPERIMENTAL
Intervention: cilazapril, 2.5 mg/day (n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo (n = 11)
Number of subjects: 23
Study: 3295741

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31621062

Group type: EXPERIMENTAL
Intervention: UHR+ BS criteria (n = 74)
Number of subjects: 133
Study: 30608395

Group type: EXPERIMENTAL
Intervention: Functional musculoskeletal therapy pathway
Number of subjects: 249
Study: 27698176

Group type: EXPERIMENTAL
Intervention: Accelerated care (deflation after 1 hour, 2 ml/10‐minute interval)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standard care (deflation after 2 hours, additional steps at 3 and 4 hours)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Accelerated care
Number of subjects: 173
Study: 25627150

Group type: EXPERIMENTAL
Intervention: Ankle destabilization boot
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ankle destabilization sandal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ankle destabilization boot and sandal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Shod condition
Number of subjects: 15
Study: 23782489

Group type: EXPERIMENTAL
Intervention: V7 (10 μg of heat-killed Mycobacterium vaccae)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: V7
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 43
Study: 22379791

Group type: EXPERIMENTAL
Intervention: Acupuncture at Back-shu points (Xinshu (BL 15), Pishu (BL 20), Gaohuang (BL 43)), once daily for 4 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (shallow layer of non-acupoints)
Number of subjects: 120
Study: 20183647

Group type: EXPERIMENTAL
Intervention: ADHD on stimulant medication
Number of subjects: 71

Group type: COMPARATOR
Intervention: ADHD on placebo
Number of subjects: 71

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 71
Study: 17363335

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 13961

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (screen-negative individuals)
Number of subjects: 13961
Study: 15865523

Group type: EXPERIMENTAL
Intervention: Bipolar TURP (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monopolar TURP (group 2)
Number of subjects: 60
Study: 11956266

Group type: EXPERIMENTAL
Intervention: Allogeneic melanoma vaccine for 2 years
Number of subjects: 300

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 300
Study: 9706157

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 544

Group type: COMPARATOR
Intervention: Operation
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Thrombolysis or Operation
Number of subjects: 544
Study: 7884105

Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistive exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise detraining for 10 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise retraining after detraining
Number of subjects: 0
Study: 2194126

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1214
Study: 495630

Group type: EXPERIMENTAL
Intervention: Carbenicillin plus cefamandole by continuous infusion (C+CC)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Carbenicillin plus cefamandole by intermittent infusion (C+IC)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Carbenicillin plus tobramycin by continuous infusion (C+T)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Cure rates regardless of antibiotic regimen
Number of subjects: 490

Group type: COMPARATOR
Intervention: Cure rates during documented infections
Number of subjects: 490
Study: 31188801

Group type: EXPERIMENTAL
Intervention: Flap surgery with autologous CGF (Group 2)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Flap surgery with Bio-Oss (Group 3)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Flap surgery with CGF+Bio-Oss (Group 4)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Flap surgery alone (Group 1)
Number of subjects: 54
Study: 28574453

Group type: EXPERIMENTAL
Intervention: DHA supplementation at 800 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (corn/soy oil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 0
Study: 25369449

Group type: EXPERIMENTAL
Intervention: High-risk coronary plaque in patients with NAFLD
Number of subjects: 445

Group type: COMPARATOR
Intervention: High-risk coronary plaque in patients without NAFLD
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Association of NAFLD with high-risk plaque
Number of subjects: 445
Study: 23548942

Group type: EXPERIMENTAL
Intervention: Single euploid blastocyst transfer
Number of subjects: 205

Group type: COMPARATOR
Intervention: Two untested blastocysts transfer
Number of subjects: 205
Study: 21565740

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19164186

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (10 mg once a day for children 10 to 24 months of age and 20 mg once a day for older children)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 700
Study: 16490909

Group type: EXPERIMENTAL
Intervention: Zoledronic acid, 4 mg (n = 32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (saline, n = 30)
Number of subjects: 62
Study: 15124834

Group type: EXPERIMENTAL
Intervention: Elemental 028 Extra (E028E)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nutrison Standard (NuS)
Number of subjects: 33
Study: 11176476

Group type: EXPERIMENTAL
Intervention: Bladder neck preservation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Resection
Number of subjects: 70
Study: 9255195

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of gentamicin (5.0 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Twice-daily dosing of gentamicin (2.5 mg/kg)
Number of subjects: 26
Study: 8370880

Group type: EXPERIMENTAL
Intervention: Iconic cues identical to the signal to be detected
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative cues set to 2/3 of the signal frequency
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cues (maximum uncertainty)
Number of subjects: 0
Study: 2950659

Group type: EXPERIMENTAL
Intervention: Polychemotherapy as a component of combined and complex therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical mastectomy for stage I tumor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified mastectomy after Patey for stage II tumor
Number of subjects: 0
Study: 31343550

Group type: EXPERIMENTAL
Intervention: High-pressure (HP) cuffing (3 × 5-minute unilateral leg occlusion at 50 mm Hg above systolic blood pressure)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-pressure (LP) cuffing (3 × 5-minute unilateral leg occlusion at 20 mm Hg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON) (30‐minute resting)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-pressure (HP) cuffing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-pressure (LP) cuffing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 28734844

Group type: COMPARATOR
Intervention: CNTO3157 (n = 30)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: CNTO3157 (n = 8)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 75
Study: 26545442

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Active rTMS and Sham stimulation
Number of subjects: 20
Study: 24716680

Group type: EXPERIMENTAL
Intervention: Spironolactone (15 to 45 mg daily)
Number of subjects: 3445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3445

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3445
Study: 23963688

Group type: EXPERIMENTAL
Intervention: 75 mg/d of ASA (aspirin)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 150 mg/d of ASA (aspirin)
Number of subjects: 125
Study: 21564429

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Chloroquine plus Sulphadoxine-Pyrimethamine (CQ + SP)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study: 18503621

Group type: EXPERIMENTAL
Intervention: Fentanyl-morphine combination (fentanyl 13.33 mug/mL and morphine 1 mg/mL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Morphine alone (2 mg/mL)
Number of subjects: 54
Study: 17070173

Group type: EXPERIMENTAL
Intervention: Higher cell dose (10^8 cells)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lower cell dose (10^7 cells)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no cell transplantation)
Number of subjects: 66
Study: 12930249

Group type: EXPERIMENTAL
Intervention: T wave alternans (TWA) measured using modified moving average (MMA) analysis from 24-hour ambulatory electrocardiograms (AECGs) during maximum heart rate.
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: TWA in lead V5 during peak heart rate.
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: TWA at 8:00 A.M. in lead V5.
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: TWA level above the 75th percentile during maximum heart rate in lead V1.
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: TWA level above the 75th percentile during maximum heart rate in lead V5.
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: TWA at 8:00 A.M. in lead V1.
Number of subjects: 1284
Study: 11193721

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with glucose/amino acids/fat
Number of subjects: 18

Group type: COMPARATOR
Intervention: Total parenteral nutrition with glucose/amino acids
Number of subjects: 18
Study: 9262798

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Philips HP550)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Manual toothbrush (Butler Gum 111)
Number of subjects: 23
Study: 8470423

Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine, 40 micrograms given at months 0, 1, 2 and 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster injection of 40 micrograms of hepatitis B vaccine in patients vaccinated before transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3297578

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Multiple injections (MI)
Number of subjects: 8
Study: 30141287

Group type: EXPERIMENTAL
Intervention: Plum-blossom needle combined with rehabilitation training
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional rehabilitation training
Number of subjects: 61
Study: 26942318

Group type: EXPERIMENTAL
Intervention: 80 mg of propranolol (beta-adrenergic receptor antagonist) administered at encoding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol administered before memory retrieval
Number of subjects: 0
Study: 23995849

Group type: EXPERIMENTAL
Intervention: Interdisciplinary care
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dermatological care
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Interdisciplinary care (patients with psychiatric disorder)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dermatological care (patients without psychiatric disorder)
Number of subjects: 47
Study: 23770172

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1790

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 1790
Study: 20092710

Group type: EXPERIMENTAL
Intervention: EN+GH group
Number of subjects: 68
Study: 17933497

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 75

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 75
Study: 16797593

Group type: EXPERIMENTAL
Intervention: Pramipexole as add-on therapy to levodopa
Number of subjects: 55

Group type: COMPARATOR
Intervention: Levodopa alone (Control)
Number of subjects: 55
Study: 12653895

Group type: EXPERIMENTAL
Intervention: One intra-arterial dose of cisplatin/lipiodol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Four doses of cisplatin/lipiodol (once every 3 months)
Number of subjects: 40
Study: 10502211

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily (group A)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Coumadin plus aspirin (group CA)
Number of subjects: 164
Study: 7854528

Group type: EXPERIMENTAL
Intervention: Lesions involving the left posterior supramarginal gyrus and the bordering parietal operculum
Number of subjects: 10
Study: 1936506

Group type: EXPERIMENTAL
Intervention: 2 x 100 mg o.d. for 1 day (87 patients)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 2 x 100 mg b.i.d. for 1 day (83 patients)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 2 x 100 mg o.d. for 2 days (86 patients)
Number of subjects: 256
Study: 7297067

Group type: EXPERIMENTAL
Intervention: 75 mg vaginal suppository of 9-deoxo-16,16-dimethyl-9-methylene PGE2
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 60 mg vaginal suppository of 9-deoxo-16,16-dimethyl-9-methylene PGE2
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 15-methyl PGF2 alpha Tham added at 24 hours
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 15-methyl PGF2 alpha Tham added at 36 hours
Number of subjects: 37

Group type: COMPARATOR
Intervention: Vaginal administration of PGE2
Number of subjects: 37

Group type: COMPARATOR
Intervention: Vaginal administration of 15-methyl PGF2 alpha methyl ester
Number of subjects: 37

Group type: COMPARATOR
Intervention: Vaginal PGE2
Number of subjects: 37
Study: 28426514

Group type: EXPERIMENTAL
Intervention: Hang Pull
Number of subjects: 18

Group type: COMPARATOR
Intervention: Jump Squat
Number of subjects: 18
Study: 28746708

Group type: EXPERIMENTAL
Intervention: Dementia care management (DCM) for 6 months
Number of subjects: 634

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 634
Study: 25540255

Group type: EXPERIMENTAL
Intervention: Bringing in the Bystander™ program
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 23263697

Group type: EXPERIMENTAL
Intervention: Post-chemotherapy interval (PCI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Breast cancer survivors (BCS)
Number of subjects: 24
Study: 21886189

Group type: EXPERIMENTAL
Intervention: Oral steroid therapy (Prednisolone, 100 mg per day for 5 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No oral steroid (control group)
Number of subjects: 28
Study: 20157975

Group type: EXPERIMENTAL
Intervention: Methodological Quality (MQ)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ethical Quality (EQ)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Correlation between MQ and EQ
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Informed Consent
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Research Ethics Committee Approval
Number of subjects: 137
Study: 17804564

Group type: EXPERIMENTAL
Intervention: Children with multiple autoantibodies (3-4 autoantibodies)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Children with two autoantibodies
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control subjects (autoantibody-negative)
Number of subjects: 85